Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN) today announced the
preliminary results of a phase I trial in metastatic breast cancer with
BN83495, Ipsen’s lead and first-in-class orally available irreversible
steroid sulfatase (STS) inhibitor. In the course of the study, the
optimal biological dose was determined as 40 mg once daily oral
administration for future phase II trials in this indication.
Preliminary results were the subject of a poster (#4097) entitled “A
Phase I Dose Escalation Study of Steroid Sulfastase Inhibitor BN83495
(STX64) in Postmenopausal Women with ER- Positive Breast Cancer”
presented at the 32nd San Antonio Breast Cancer Symposium
held from December 9 to December 13, 2009, in San Antonio (Texas, USA).
The compound is currently in further clinical development for advanced
endometrial cancer (phase II) as well as in Phase I clinical evaluation
for castrate resistant prostate cancer in North America.